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 26 
Abstract 27 
Background Venous thromboembolism (VTE) is a well-recognised and life-28 
threatening complication in patients with cancer. However, the precise risk of VTE in 29 
hospitalised cancer patients in England has not been previously reported.  30 
Methods We conducted a cohort study using linked Hospital Episodes Statistics 31 
and Office for National Statistics mortality data. We determined the risk of VTE 32 
separately for 24 cancer sites following first hospitalisation for cancer (index date) 33 
and how this varied by age, proximity from hospital admission, administration of 34 
chemotherapy and calendar time.  35 
Results 3,558,660 patients were hospitalised for cancer between 1998 and 2012. 36 
The cancer sites with the highest risk of VTE during initial hospitalisation for cancer 37 
were pancreatic (4.9%), ovarian (4%) and liver (3.8%). The three cancer sites with 38 
the highest risk of first VTE event within 6 months from discharge, were pancreatic 39 
(3.7%), oesophagus (3%) and stomach (2.8%). For most cancers, the risk of VTE 40 
within 6 months from discharge was higher amongst patients who underwent 41 
chemotherapy compared to those who did not. The impact of age on risk of VTE 42 
varied considerably between cancer sites.  43 
Conclusion The risk of VTE amongst patients hospitalised for cancer varies greatly 44 
by cancer site, age, proximity from hospital admission and chemotherapy 45 
administration.  46 
 47 
Keywords: cancer, venous thrombosis, hospitalisation, epidemiology, 48 
chemotherapy 49 
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1 Introduction 51 
Venous thromboembolism (VTE) is responsible for approximately 25,000 deaths 52 
each year in the UK and it is well established that patients with cancer are at higher 53 
risk of VTE compared to the general population.1-3 The estimated annual incidence 54 
of VTE in the cancer population is 1.3% and the risk of death is higher for cancer 55 
patients with VTE than for those without.4-8 Given the ageing population and 56 
increased early diagnosis, more people are living with cancer in the UK than ever 57 
before.9 Therefore prevention of a potentially fatal cancer associated-VTE among 58 
patients is of paramount importance. Furthermore, the long-term consequences of VTE 59 
such as post thrombotic syndrome (PTS) are more of an issue now as people with cancer 60 
are living long enough now to develop them. The cost to the NHS for management of PTS is 61 
significant and covered in the Department of Health enquiring into VTE (ref??) 62 
Current UK guidelines, published by the National Institute for Health and Care 63 
Excellence (NICE), recommends prophylaxis for VTE for cancer patients admitted to 64 
hospital, but only routinely to those hospitalised for 3 or more days or who are 65 
expected to have ongoing reduced mobility.10 Prophylaxis is cheap and highly 66 
effective (around 50 to 70% reduction)11,12 however to prevent unnecessary harm 67 
from thromboprophylaxis and its associated adverse effects, careful consideration 68 
must be given to identify patients who are most at risk so that prophylaxis can be 69 
appropriately targeted. 70 
Previous studies and a recent report from the Centers for Disease Control and 71 
Prevention confirm hospitalisation is an important risk factor for VTE, and 72 
emphasise the need for greater awareness of VTE risks and implementation of 73 
preventative measures in hospital.13,14 To date, a limited number of hospital-based 74 
studies in patients with cancer (outside of the UK only) have been conducted; and 75 
the majority of studies did not determine the risk of VTE following discharge.15-18  Of 76 
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the two that did, one study was limited to a select patient group and the other did 77 
not determine how risk of re-admission for VTE varies by potential risk factors.15,16 78 
There is therefore a need for a hospital-based cohort study in patients with cancer in 79 
England to determine contemporary and precise estimates of the risk of VTE, taking 80 
into account risk factors such as age, cancer site, proximity from admission and 81 
chemotherapy administration. Such risk stratification could be used to inform future 82 
clinical guidelines and optimise the use of prophylactic anticoagulation when 83 
patients are admitted to hospital with cancer. 84 
This study uses the English Hospital Episode Statistics (HES) and linked Office for 85 
National Statistics (ONS) death certificate data to determine the risk of VTE in 86 
hospitalised cancer patients, during admission and post discharge, and stratified by 87 
risk factors. 88 
 89 
2 Methods 90 
2.1 Data source and Patients 91 
We conducted a cohort study using the Hospital Episode Statistics (HES) database, 92 
which contains details on all inpatient and day case admissions to English NHS 93 
hospitals from 1989. More than 12 million admission records are added each year.19 94 
The database is managed by the Health and Social Care Information Centre and 95 
contains data on hospitalisations, which are broken down into periods of care seen 96 
by consultants (episodes). The primary diagnosis per episode is indicated. A 97 
diagnosis is coded using the ICD-10 (International Classification of Diseases, 10th 98 
revision) and a procedure is coded using the OPCS-4 (Office of Population, 99 
Censuses and Surveys’ classification of surgical operations and procedures, fourth 100 
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revision). HES is linked to the ONS death registry which provides date of death for 101 
all deceased patients. 102 
We selected patients who had a first cancer diagnosis recorded in HES (ICD-10 103 
Chapter II, C00-C97, excluding non-melanoma skin cancer) between 1st January 104 
1998 and 31st October 2012, as this was the period the HES data were available for 105 
at the time of writing. Patients who had a VTE event were identified. Patients were 106 
excluded if: 107 
 Under 18 years of age at first cancer diagnosis 108 
 Had a VTE diagnosis in a hospital admission prior to the cancer admission  109 
Data were analysed separately for the 24 most common cancer sites (based on 110 
2007 UK incidence data). Cancer sites not included within these were categorised 111 
as ‘Other’. ‘Unknown primary’ site consisted of metastatic cancers with no known 112 
primary cancer site (C77-C80). Cancer site classification was based on the first 113 
occurring cancer and the corresponding date was assumed to be the date of 114 
diagnosis (termed index date from this point onwards).  Ethical approval was given 115 
by the ONS for this study (reference number RU863/NIC-165667-FH1W1). 116 
2.2 VTE event 117 
For the cancer patients, aA VTE diagnosis was defined as (i) having a hospital 118 
admission for pulmonary embolism (ICD-10, I26) or venous thrombosis (ICD-10, 119 
I80, I81 or I82) or (ii) having one of the above codes as underlying cause of death. 120 
The first VTE event concurrent with or following the index date was selected as the 121 
outcome of interest.  122 
 123 
 124 
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 126 
2.3 Chemotherapy 127 
Patients receiving inpatient therapy were identified using OPCS-4 codes for 128 
chemotherapy (X72.1, X72.2, X72.3 and X73.1). 129 
2.4 Statistical methods 130 
The risk of VTE was stratified by timing of first VTE event, that is, whether the event 131 
occurred during the same hospitalisation as the index date or as re-admission in the 132 
6 months following discharge; for all 24 cancers sites. Further stratification by age-133 
group (<60, 60-80 and >80 years) was performed for the four most commonly 134 
diagnosed cancers in the UK (Breast, Lung, Bowel and Prostate), those found to be 135 
at high risk of VTE (according to our data) and all cancers combined. The relative 136 
risk of first VTE as a re-admission within 6 months from discharge amongst those 137 
who had a record of chemotherapy compared to those who did not was determined 138 
using logistic regression, for all cancer sites. 139 
Trends in VTE risk over time (assigning patients to year of index date) were 140 
investigated for the four most commonly diagnosed cancers. Patients whose first 141 
VTE event was concurrent with their index date were removed from this analysis to 142 
ensure the VTE event was subsequent to the cancer diagnosis. Patients whose 143 
index date was in 2012 were also excluded from this part of the analysis as data 144 
were not available for the full calendar year.  To control for differing length of 145 
hospital stay (a marker of cancer severity), we repeated the analysis stratified by 146 
short term (<3 days) and prolonged stay (≥3 days). This cut off was chosen 147 
according to NICE VTE guidelines (NICE guidelines, 2010).  We also conducted a 148 
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sensitivity analysis to determine if trends for the whole cohort were different to the 149 
subgroup of patients whose primary diagnosis was cancer.  150 
In addition to risk, absolute rates of VTE were determined to account for varying 151 
length of survival by type of cancer. The rates were presented by cancer site and 152 
timing of VTE event in relation to hospitalisation: during hospitalisation or six months 153 
post-discharge.  Person-time at risk commenced at the time of index date or time 154 
from discharge for each respective group. Patients were followed up until they 155 
developed a VTE event, died, six months post-discharge, or 31st October 2012 (last 156 
data collection date), whichever was earliest. Rates were calculated as the number 157 
of first VTE events divided by person-time (per 1000 person-years). VTE events 158 
concurrent with start of follow-up were excluded (as these patients did not contribute 159 
person-time years). All data management and statistical analysis were performed 160 
using Stata 12 (Statacorp, 4905 Lakeway Drive, College Station, Texas 77845, 161 
USA).  162 
 163 
3. Results 164 
3.1 Patients 165 
A total of 3,558,680 patients were identified with a hospital admission for cancer 166 
between 1998 and 2012. The median age at index date was 70 [IQR 59.6, 78.7] 167 
years. Of these patients, 108,770 (3.06%) had a VTE anytime between index date 168 
and up to 6 months from discharge; just under two-thirds of these (n=66,954; 169 
61.6%) had their first VTE during the hospitalisation for cancer (Table 1). 170 
 171 
 172 
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Table 1 Patient characteristics 179 
Characteristic No.patientsa % 
Sex     
Male 1,803,145 50.7 
Female 1,755,535 49.3 
Age at first cancer diagnosis (years)     
18-40 154,617 4.3 
41-60 761,059 21.4 
61-80 1,879,373 52.8 
>80 763,631 21.5 
Mean (SD) 68.2 (14.3)   
Median [IQR] 70 [59.6, 78.7]   
Follow-up time (years)     
Total 12,028,985   
Median [IQR] 1.70 [0.33, 5.46]   
First VTE event     
During hospitalisation 66,954 43.02* 
Within 6 months following discharge 41,816 26.87* 
Beyond 6 months following discharge 46,880 30.12* 
Entire study 155,650   
 a unless otherwise stated; SD=standard deviation; IQR=Interquartile range; * of total number of 180 
patients who had a VTE during the entire study. 181 
 182 
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 188 
3.2 Risk of first VTE by cancer site and timing from index date 189 
For the majority of cancers, the risk of VTE during hospitalisation was higher than in 190 
the first six months post-discharge (1.88% vs.1.42% respectively, overall) (Table 2). 191 
The cancer sites with the highest proportion of VTE events during initial 192 
hospitalisation for cancer were pancreatic (4.89%), ovarian (4.01%) and liver 193 
(3.84%). In contrast, VTE occurred in less than 0.5% of patients with malignant 194 
melanoma, oral and laryngeal cancer.  Of the 2,943,792 patients alive at discharge 195 
and without a prior VTE event, the three cancer sites with the highest risk of a VTE 196 
within 6 months were pancreatic (3.66%), oesophagus (2.98%) and stomach 197 
(2.84%).  198 
 199 
3.3 Risk of VTE by age and timing from index date 200 
For all cancers combined, the risk increased from 1.4% in those less than 60 years 201 
to 2.3% in those over 80 years (Table 3). However, for the cancers we considered 202 
with a poor prognosis (lung, liver and pancreatic) the risk of VTE during 203 
hospitalisation decreased with age.   204 
3.4 Trends of VTE by calendar year  205 
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Figs 1 - 2 display the risk of VTE during hospitalisation and within 6 months of 206 
discharge, respectively, by year of index date. With respect to the risk during 207 
hospitalisation, the trends varied by cancer site. Overall, the risk decreased with 208 
time, especially for breast and prostate cancer. In contrast, for lung cancer, the risk 209 
of VTE increased between 1998 and 2008. With respect to the risk of VTE as a re-210 
admission, there was an overall increase over the calendar period. The increase 211 
was relatively small for breast and prostate but significant for lung and bowel, 212 
increasing 2-fold for lung and just over 50% for bowel from 1998 to 2011. 213 
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Table 2 First VTE event (%) stratified by cancer site and timing of event, up to 6 months from discharge 
First VTE event During hospitalisation     Within 6 months following discharge Total   
Cancer site No. people No. with VTE % No. people  No. with VTE % 
 
No. with VTE  % 
        alive at discharge & no 
previous VTE 
   
 
    
Breast  525,053 4,843 0.92 485,009 3,643 0.75 525,053 8,486 1.62 
Lung 395,671 9,808 2.48 278,182 6,436 2.31 395,671 16,244 4.11 
Bowel 432,308 7,369 1.70 364,489 5,635 1.55 432,308 13,004 3.01 
Prostate 384,078 5,876 1.53 335,231 2,191 0.65 384,078 8,067 2.10 
Non-hodgkin lymphoma 134,096 2,979 2.22 113,989 2,155 1.89 134,096 5,134 3.83 
Malignant melanoma 86,496 318 0.37 82,445 155 0.19 86,496 473 0.55 
Bladder 241,152 2,057 0.85 217,217 1,547 0.71 241,152 3,604 1.49 
Kidney 73,273 2,229 3.04 60,755 724 1.19 73,273 2,953 4.03 
Oesophageal 98,668 1,395 1.41 79,812 2,379 2.98 98,668 3,774 3.82 
Stomach 86,454 2,044 2.36 66,314 1,886 2.84 86,454 3,930 4.55 
Pancreatic 78,579 3,846 4.89 52,296 1,915 3.66 78,579 5,761 7.33 
Leukemia 108,405 1,913 1.76 86,648 928 1.07 108,405 2,841 2.62 
Uterus 74,346 1,113 1.50 68,516 705 1.03 74,346 1,818 2.45 
Ovarian 70,613 2,834 4.01 57,162 1,314 2.30 70,613 4,148 5.87 
Oral 69,827 301 0.43 62,784 378 0.60 69,827 679 0.97 
Brain 69,362 1,545 2.23 55,107 1,353 2.46 69,362 2,898 4.18 
Multiple myeloma 59,610 1,058 1.77 48,944 1,033 2.11 59,610 2,091 3.51 
Liver 52,242 2,005 3.84 36,485 783 2.15 52,242 2,788 5.34 
Cervix 33,618 530 1.58 30,596 459 1.50 33,618 989 2.94 
Laryngeal 25,918 127 0.49 22,879 86 0.38 25,918 213 0.82 
Testicular 22,985 172 0.75 22,481 201 0.89 22,985 373 1.62 
Bone/connecive tissue 30,023 483 1.61 26,490 293 1.11 30,023 776 2.58 
Thyroid 22,718 122 0.54 21,368 56 0.26 22,718 178 0.78 
Mesothelioma 22,354 361 1.61 17,350 349 2.01 22,354 710 3.18 
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Other site 102,771 1,792 1.74 87,853 1,190 1.35 102,771 2,982 2.90 
Unknown 258,040 9,834 3.81 163,390 4,022 2.46 258,040 13,856 5.37 
Total 3,558,660 66,954 1.88 2,943,792 41,816 1.42 3,558,660 108,770 3.06 
 
Table 3 First VTE event (%) during hospitalisation stratified by cancer site and age-group  
  Age (years) 
Cancer site <60     60-80     >80     
During hospitalisation No. people No. with VTE  % No. people No. with VTE  % No. people No. with VTE % 
Breast  231,286 1166 0.50 220,311 2112 0.96 73,456 1565 2.13 
Lung 60,594 1820 3.00 249,044 5775 2.32 86,033 2213 2.57 
Bowel 76,305 984 1.29 247,306 4068 1.64 108,697 2317 2.13 
Prostate 32,460 255 0.79 239,913 3516 1.47 111,705 2105 1.88 
Ovarian 25,834 740 2.86 34,245 1527 4.46 10,534 567 5.38 
Pancreatic 13,278 700 5.27 44,386 2259 5.09 20,915 887 4.24 
Liver 11,020 514 4.66 28,717 1101 3.83 12,505 390 3.12 
All cancers 915,676 12,787 1.40 1,879,373 36,692 1.95 763,631 17,475 2.29 
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 1 
3.5 Trends of VTE by calendar year stratified by length of stay 2 
When stratified by hospital duration, the reduction of VTE over time is less 3 
pronounced for breast cancer but the rise amongst lung cancer patients still remains 4 
(Supplementary Fig 1). Trends by length of stay were similar between the overall 5 
cohort (Supplementary Fig 1) and the subgroup of patients whose primary diagnosis 6 
was cancer (Supplementary Fig 2). 7 
 8 
3.6 Risk of VTE by chemotherapy  9 
Of the study population, a total of 719,257 patients (20.2%) received inpatient 10 
chemotherapy during the study period and the median time from index date to 11 
chemotherapy was 46 [IQR 16, 104] days. The number of people who received 12 
chemotherapy during their initial hospitalisation was 250,638 (7%). Of those who 13 
were discharged without a VTE, and followed-up for up to six months, 22.7% 14 
received chemotherapy (Table 4). For these patients, the odds ratio of VTE in those 15 
who underwent chemotherapy compared to those who did not was 1.75 (95% CI 16 
1.72, 1.79). The cancer sites associated with the highest risk of VTE within six 17 
months from discharge, if chemotherapy was undertaken, were pancreatic (5.2%), 18 
stomach (4.87%) and oesophageal (4.67%). The cancer sites with the highest risk 19 
of VTE amongst patients not receiving chemotherapy were pancreatic (3.20%), 20 
brain (2.52%) and ovarian (2.43%). For all cancer sites, except brain, ovarian, 21 
multiple myeloma and oral cancer, the proportion of chemotherapy patients who had 22 
a VTE event was statistically significantly higher than those who did not undergo 23 
treatment (p<0.05 for all instances).  24 
 25 
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Table 4 First VTE event within 6 months from discharge (%) stratified by cancer site and chemotherapy 
Cancer site No. people alive 
and no VTE 
during 
hospitalisation 
Chemotherapy VTE % No chemotherapy VTE  % 
Breast  485,009 138,776 1871 1.35 346,233 1772 0.51 
Lung 278,182 71,155 2389 3.36 207,027 4047 1.95 
Bowel 364,489 96,577 1853 1.92 267,912 3782 1.41 
Prostate 335,231 17,687 180 1.02 317,544 2011 0.63 
Non-hodgkin lymphoma 113,989 60,495 1165 1.93 53,494 990 1.85 
Malignant melanoma 82,445 4,088 20 0.49 78,357 135 0.17 
Bladder 217,217 32,418 291 0.90 184,799 1256 0.68 
Kidney 60,755 4,458 61 1.37 56,297 663 1.18 
Oesophageal 79,812 22,786 1063 4.67 57,026 1316 2.31 
Stomach 66,314 14,916 726 4.87 51,398 1160 2.26 
Pancreatic 52,296 12,015 625 5.20 40,281 1290 3.20 
Leukemia 86,648 23,957 287 1.20 62,691 641 1.02 
Uterus 68,516 7,615 146 1.92 60,901 559 0.92 
Ovarian 57,162 28,259 613 2.17 28,903 701 2.43 
Oral 62,784 12,080 114 0.94 50,704 264 0.52 
Brain 55,107 6,726 135 2.01 48,381 1218 2.52 
Multiple myeloma 48,944 18,175 348 1.91 30,769 685 2.23 
Liver 36,485 5,228 155 2.96 31,257 628 2.01 
Cervix 30,596 7,651 177 2.31 22,945 282 1.23 
Laryngeal 22,879 2,711 15 0.55 20,168 71 0.35 
Testicular 22,481 9,119 103 1.13 13,362 98 0.73 
Bone/connecive tissue 26,490 4,231 78 1.84 22,259 215 0.97 
Thyroid 21,368 717 3 0.42 20,651 53 0.26 
Mesothelioma 17,350 4,908 120 2.44 12,442 229 1.84 
Other site 87,853 36,920 476 1.30 50,933 714 1.40 
15 
 
Unknown 163,390 25,095 1128 4.49 138,295 2894 2.09 
Total 2,943,792 668,763 14142 2.11 2,275,029 27674 1.22 
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3.7 VTE rates by cancer site and timing from index date 1 
For all cancer sites, the absolute rate of VTE was higher during hospitalisation compared 2 
with rates in the first 6 months following discharge. In the first six months following 3 
discharge, the cancer sites associated with the highest rates were pancreatic (11.9 per 1000 4 
person-years; CI 11.3-12.4), oesophageal (7.8; CI 7.4-8.1) and lung (6.8; CI 6.7-7.0). The 5 
overall rate of VTE was 3.34 per 1,000 person-years (95% CI 3.31-3.37). (Supplementary 6 
Fig 3).  7 
 8 
4. Discussion 9 
4.1 Main findings 10 
We found that more people developed VTE in their initial hospitalisation than in the 11 
subsequent six months, for most cancer types. Regardless of how we assessed VTE, 12 
pancreatic cancer was associated with the highest risk of VTE of all measured cancer types, 13 
both overall and specifically amongst those who underwent chemotherapy. The overall risk 14 
of VTE in people hospitalised for cancer was 3.06% and overall varied from 1.88% during 15 
hospitalisation to 1.42% within 6 months from discharge; in those with pancreatic cancer the 16 
equivalent risk was 4.89% and 3.66% respectively. For cancer types with a poor prognosis 17 
(e.g. lung) there was a negative association between age and risk of VTE. For most cancer 18 
types, the risk of VTE within six months from discharge was higher amongst those who 19 
received chemotherapy than those who did not. Compared with previous work, we found 20 
important differences in time trends depending on whether VTE was assessed during the 21 
initial hospitalisation or in the ensuing six months. In particular, re-admission rates for VTE 22 
from 1998 to 2011, increased by 2-fold in patients with lung cancer and 50% in those with 23 
bowel cancer. 24 
 25 
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4.2 Strengths and Limitations  26 
This is the first study to describe the risk of VTE in a hospitalised cancer population in the 27 
UK, and is one of the largest studies worldwide on this topic. The large sample size gives 28 
precise risk estimates stratified by cancer type, including those of lower prevalence. As the 29 
HES database incorporates all inpatient and day case hospital admissions taking place in 30 
England, our results are nationally generalisable. Moreover, we have been able to 31 
distinguish VTE events which were recorded during the cancer admission from those 32 
recorded in re-admissions over the subsequent 6 months, providing novel information that 33 
can be used in a clinical setting. 34 
The main weakness of the study is lack of detail in HES to establish whether VTE is the 35 
cause or consequence of hospitalisation when assessing VTE as baseline. This is a 36 
limitation inherent in all hospital-based studies using discharge notes, as primary diagnosis 37 
is not necessarily the reason for hospitalisation. A further limitation of this study is the 38 
reliability of the diagnostic coding for VTE in HES. This is in terms of sensitivity, as not all 39 
VTE events may be recorded in secondary care; as well as specificity, as data to support a 40 
VTE diagnosis, such as evidence of anticoagulant treatment, are not available in HES. As 41 
we did not have access to outpatient data, and given that the majority of cancer-associated 42 
VTE is diagnosed and managed as an outpatientcan be treated outside hospital,20 our 43 
estimates of the risk of VTE post discharge are most probably underestimated. Thus, the 44 
true burden of VTE in hospitalised cancer patients post discharge may be greater than we 45 
report. 46 
Similar to previous studies, we lack information on potential confounders such as stage of 47 
disease and comorbidity which have been shown to be associated with risk of VTE. These 48 
variables could explain why patients with certain cancer types, and those undergoing 49 
chemotherapy, have a higher risk of VTE than others.14,20 Finally, as in the case of other 50 
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studies, it is likely that we have underestimated the number of people receiving 51 
chemotherapy as we have only included therapy during hospital admission.  52 
4.3 Comparison with other studies  53 
This current study is consistent with the findings of previous work, that pancreatic cancer is 54 
associated with the highest risk of VTE amongst patients hospitalised for cancer.16-18   Bloom 55 
et al, (2004, 2005) conducted hospital-based studies in the Netherlands and reported a risk 56 
of 7.4% and 3.9% by 6 months from diagnosis for pancreatic and lung cancer over the 57 
period 1990 to 2000, our equivalent results are 7.3% and 4.1% respectively.21,22 58 
With respect to the risk of VTE during hospitalisation, our study is best compared to that by 59 
Khorana et al (2007).18 The authors established a cohort of 1,015,598 cancer patients 60 
between 1996 and 2003 at 133 United States medical centres. The overall risk of VTE 61 
during hospitalisation was 4.1%, almost double the risk we report. The risk of VTE may be 62 
higher in the US compared to the UK due to true population differences or different case 63 
ascertainment and/or use of prophylaxis. A study by Stein et al (2006). conducted between 64 
1979 and 1999 report the risk to be 2% overall, and highlighting a more than 2-fold  increase 65 
in VTE in cancer patients between 1979 and 1999.17 66 
The studies by Levitan et al (1999) and a separate US study specifically including patients 67 
with neutropenia (Khorana et al, 2006) both demonstrated that the risk of re-admission for 68 
VTE is smaller than during initial hospitalisation, 0.14% vs. 0.6% and 5.7% vs. 6.7%, 69 
respectively.15,16 A similar pattern was found in this current study (1.42% vs. 1.88%). This 70 
could be a result of co-morbidities, infections, lack of mobility or the effect of various 71 
treatments during hospitalisation, which are all associated with risk of VTE.23-28 72 
With respect to the association between age and risk of VTE in cancer patients, there are 73 
inconsistent findings in the literature. Some report that patients older than 65 years are at 74 
greater risk of VTE whereas others report that the incidence of VTE in cancer patients is not 75 
age dependent.16,18,29 We have found, in general, that risk of VTE increases with age during 76 
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initial hospitalisation, apart from cancers with a poor prognosis. The former could be due to 77 
increasing baseline risk of VTE with age. (ref) The latter finding could be due to older 78 
patients with a poor prognosis being more likely to die before having a VTE than younger 79 
patients. 80 
Regarding the effect of treatment on the risk of VTE, the study by Khorana et al (2007) is the 81 
only previous hospital-based study to examine the association between VTE event and 82 
chemotherapy.18 The authors report that the risk of VTE was higher amongst patients who 83 
underwent chemotherapy, than those who did not (in agreement with this current study). 84 
However because the study was not prospective they were unable to explore the risk of re-85 
admission of VTE, neither were results for chemotherapy stratified by cancer type.  One 86 
other limitation of the study is that the authors randomly selected a single hospitalisation for 87 
patients with multiple hospitalisations and only included chemotherapy during the 88 
hospitalisation being analysed. In our study we have also included episodes of 89 
chemotherapy delivered in subsequent day case admissions and as such would have 90 
captured this information more comprehensively. This could explain why we found a higher 91 
proportion of patients undergoing chemotherapy (20%)  compared to  Khorana et al (14%).18 92 
Previous studies have reported an increase in VTE rates in cancer patients over time.17,18,29 93 
To our knowledge, only one study has stratified rates by cancer site and demonstrated how 94 
the increase in rates over calendar period was higher in those with a greater rate of VTE.29  95 
We have demonstrated that the trends in VTE vary not only by cancer site but whether the 96 
VTE event occurred during hospitalisation (adjusting for length of stay) or following 97 
discharge, with subsequent VTE in patients with cancers of the lung having increased 98 
markedly over the 14 year study period. 99 
 100 
 101 
 102 
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 103 
4.4 Clinical implications  104 
Given that our study and others highlight the varying risk of VTE by cancer site and the 105 
higher risk in hospital compared to post discharge, careful consideration of the patients that 106 
would and would not benefit from prophylaxis following hospitalisation is required. For 107 
example, young patients with malignant melanoma may experience a net harm from taking 108 
in-hospital prophylaxis whereas young patients with pancreatic, lung or liver cancer may 109 
benefit. One could argue, however, that for patients with pancreatic cancer, who are at such 110 
advanced disease stage and in poor health in general, that prevention of VTE may not be 111 
cost effective as they are likely to die short term for other reasons. The relatively low risk of 112 
VTE in patients with myeloma could reflect clinicians’ use of routine prophylaxis during 113 
chemotherapy as an outpatient. 114 
Our work adds to ongoing research investigating the association of chemotherapy with the 115 
development of VTE in patients with cancer. Such an association has been shown in several 116 
studies.30-33 For example, in one population-based case-control study, patients receiving 117 
chemotherapy had a higher odds ratio for the development of VTE (6.5) than those not 118 
receiving chemotherapy (4.1), when compared with patients without cancer.2 Our group’s 119 
recent work on VTE in breast cancer showed the risk of VTE was 10-fold when 120 
chemotherapy was treated as a time-varying covariate. Due to limitations of the data in this 121 
current study, we have only been able to crudely analyse the effect of chemotherapy on risk 122 
of VTE. 123 
Khorana et al, (2008) published a risk assessment model to estimate the risk of VTE in 124 
patients with cancer receiving chemotherapy (4066 patients) which has set the stage for 125 
randomised clinical trials in this area.34 In this risk model, cancers of the stomach and 126 
pancreas were classed as very high risk. Such a classification was supported by data from 127 
the sub-group of patients in our study who underwent chemotherapy (which took place an 128 
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average of 46 days into the 6 month interval), with a high VTE risk (>4%) also occurring 129 
among people with oesophageal cancer. Such information could be used to influence the 130 
introduction of chemotherapy as a risk factor into some guidelines for specific sub-groups of 131 
patients, as has been suggested by the National Comprehensive Cancer Network.35 132 
We have demonstrated that trends of VTE over time vary considerably by cancer site. For 133 
example, in patients with lung cancer the risk of VTE during hospitalisation doubled between 134 
1998 and 2008 (even after adjusting for length of hospital stay), whereas it fell or only slightly 135 
increased for all other cancers. This rise may be explained by greater ascertainment by 136 
computerised tomography (CT) scan rather than a real rise. Patients with lung cancer are 137 
most likely to get follow up CT scans than patients with other cancers and there is increasing 138 
CT availability and increasing resolution of scans in the UK.  139 
 140 
 141 
 142 
4.5 Conclusion  143 
This is the first hospital-based study to report the risk of VTE amongst patients with cancer in 144 
the UK. When considering clinical guidelines for inpatients, cancer site may need to be taken 145 
into account, especially as the risk varies from 0.37% (malignant melanoma) to 4.89% 146 
(pancreas). There could be more of a focus on early prophylactic use amongst the high risk 147 
cancers immediately following hospitalisation, especially amongst younger patients with 148 
pancreatic cancer; and consideration of chemotherapy, as a potential risk factor, in future 149 
clinical decision-making may be required. 150 
 151 
 152 
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Figure Legends 283 
Figure 1: Percentage of patients with first VTE during hospitalisation by year of cancer diagnosis  284 
 285 
Figure 2: Percentage of patients with first VTE within 6 months following discharge by year of cancer 286 
diagnosis 287 
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